Quick Answer
Cabaletta Bio, Inc. reported Operating Income Loss of -$172.24 million for the year ending 2025.
- Cabaletta Bio, Inc. showed a decrease of -37.6% in Operating Income Loss from 2024 to 2025.
- This data is from Cabaletta Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2018: -$3.08 million | Q1 2019: -$3.99 million | Q2 2019: -$3.80 million | Q3 2019: -$5.03 million | Q1 2020: -$7.90 million | Q2 2020: -$8.19 million | Q3 2020: -$8.42 million | Q1 2021: -$9.71 million | Q2 2021: -$11.15 million | Q3 2021: -$11.56 million | Q1 2022: -$13.00 million | Q2 2022: -$13.06 million | Q3 2022: -$11.78 million | Q1 2023: -$16.96 million | Q2 2023: -$15.89 million | Q3 2023: -$18.67 million | Q1 2024: -$28.03 million | Q2 2024: -$30.28 million | Q3 2024: -$33.05 million | Q1 2025: -$37.14 million | Q2 2025: -$45.91 million | Q3 2025: -$46.59 million.
- Over the full 8 years of available data (2018 to 2025), Cabaletta Bio, Inc.'s Operating Income Loss has declined by 2,681.2%.
- Historical annual values: Fiscal year 2025: -$172.24 million | Fiscal year 2024: -$125.14 million | Fiscal year 2023: -$74.66 million | Fiscal year 2022: -$54.14 million | Fiscal year 2021: -$46.31 million | Fiscal year 2020: -$33.83 million | Fiscal year 2019: -$18.68 million | Fiscal year 2018: -$6.19 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: